| A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable A Cortellini, M Bersanelli, S Buti, K Cannita, D Santini, F Perrone, R Giusti, ... Journal for ImmunoTherapy of Cancer 7 (1), 57, 2019 | 331 | 2019 |
| Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab U De Giorgi, G Procopio, D Giannarelli, R Sabbatini, A Bearz, S Buti, ... Clinical Cancer Research 25 (13), 3839-3846, 2019 | 175 | 2019 |
| Clinical Outcomes of Patients with Advanced Cancer and Pre‐Existing Autoimmune Diseases Treated with Anti‐Programmed Death‐1 Immunotherapy: A Real‐World Transverse Study A Cortellini, S Buti, D Santini, F Perrone, R Giusti, M Tiseo, M Bersanelli, ... The oncologist, 10.1634/theoncologist.2018-0618, 2019 | 152 | 2019 |
| Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients A Cortellini, R Chiari, B Ricciuti, G Metro, F Perrone, M Tiseo, M Bersanelli, ... Clinical lung cancer 20 (4), 237-247. e1, 2019 | 136 | 2019 |
| Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the … E Verzoni, G Cartenì, E Cortesi, D Giannarelli, A De Giglio, R Sabbatini, ... Journal for ImmunoTherapy of Cancer 7 (1), 99, 2019 | 124 | 2019 |
| Chemotherapy in metastatic renal cell carcinoma today? A systematic review S Buti, M Bersanelli, A Sikokis, F Maines, F Facchinetti, E Bria, A Ardizzoni, ... Anti-Cancer Drugs, 2013 | 117 | 2013 |
| The Circulating Pool of Functionally Competent NK and CD8+ Cells Predicts the Outcome of anti-PD1 Treatment in Advanced NSCLC G Mazzaschi, F Facchinetti, G Missale, D Canetti, D Madeddu, A Zecca, ... Lung Cancer 127, 153-163, 2019 | 102 | 2019 |
| Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/Programmed cell death … A Cortellini, M Bersanelli, D Santini, S Buti, M Tiseo, K Cannita, F Perrone, ... European Journal of Cancer 128, 17-26, 2020 | 95 | 2020 |
| Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study C Masini, C Iotti, U De Giorgi, RS Bellia, S Buti, F Salaroli, I Zampiva, ... European Urology, 2021 | 92* | 2021 |
| Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors M Santoni, A Conti, S Partelli, C Porta, CN Sternberg, G Procopio, ... Annals of surgical oncology 22 (6), 2094-2100, 2015 | 88 | 2015 |
| Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study CA Nebhan, A Cortellini, W Ma, T Ganta, H Song, F Ye, R Irlmeier, ... JAMA oncology 7 (12), 1856-1861, 2021 | 85 | 2021 |
| Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and … S Buti, M Bersanelli, F Perrone, M Tiseo, M Tucci, V Adamo, LS Stucci, ... European Journal of Cancer 142, 18-28, 2021 | 85 | 2021 |
| Adjuvant Low-Dose Interleukin-2 (IL-2) Plus Interferon-α (IFN-α) in Operable Renal Cell Carcinoma (RCC): A Phase III, Randomized, Multicentre Trial of the Italian Oncology … R Passalacqua, C Caminiti, S Buti, C Porta, R Camisa, L Braglia, ... Journal of Immunotherapy 37 (9), 440-447, 2014 | 81 | 2014 |
| Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real‐world results from an expanded access programme U De Giorgi, G Cartenì, D Giannarelli, U Basso, L Galli, E Cortesi, ... BJU international, doi: 10.1111/bju.14461, 2018 | 77 | 2018 |
| From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis M Bersanelli, S Buti World Journal of Clinical Oncology 8 (1), 37-53, 2017 | 77 | 2017 |
| Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors L Schirosi, N Nannini, D Nicoli, A Cavazza, R Valli, S Buti, L Garagnani, ... Annals of oncology 23 (9), 2409-2414, 2012 | 77 | 2012 |
| Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression≥ 50%: a multicenter study with external validation A Cortellini, B Ricciuti, M Tiseo, E Bria, GL Banna, JGJV Aerts, F Barbieri, ... Journal for ImmunoTherapy of Cancer 8 (2), e001403, 2020 | 75 | 2020 |
| Soluble PD-L1 and Circulating CD8+ PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients G Mazzaschi, R Minari, A Zecca, A Cavazzoni, V Ferri, C Mori, A Squadrilli, ... Lung Cancer 148, 1-11, 2020 | 73 | 2020 |
| Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of≥ 50% A Cortellini, M Tiseo, GL Banna, F Cappuzzo, JGJV Aerts, F Barbieri, ... Cancer Immunology, Immunotherapy 69 (11), 2209-2221, 2020 | 68 | 2020 |
| Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma M Santoni, A Conti, C Porta, G Procopio, CN Sternberg, U Basso, ... The Journal of urology 193 (1), 41-47, 2015 | 68 | 2015 |
